Khalid E Ahmed, Dima Abu Nasrieh, Haneen A Banihani, Mohammed Fadi Obaidat, Toni Mazzawi, Azzah Khalid Al-Tarawneh, Radwan Bani Mustafa, Zaid Al Kayed
{"title":"Exploring Jordanian Physicians' and Medical Students' Perspectives on Ketamine and Psychedelic-Assisted Therapies: An Insight from the Middle East.","authors":"Khalid E Ahmed, Dima Abu Nasrieh, Haneen A Banihani, Mohammed Fadi Obaidat, Toni Mazzawi, Azzah Khalid Al-Tarawneh, Radwan Bani Mustafa, Zaid Al Kayed","doi":"10.1080/02791072.2025.2526403","DOIUrl":"https://doi.org/10.1080/02791072.2025.2526403","url":null,"abstract":"<p><p>Psychedelic-assisted therapies and ketamine are two modalities gaining attention in psychiatry for treating conditions such as depression, PTSD, and substance use disorders. However, perceptions of these treatments vary globally. This study explores the familiarity, attitudes, and perceptions of Jordanian physicians and medical students toward psychedelic substances, addressing a gap in Middle Eastern research. A cross-sectional study conducted from July to August 2024 utilized a validated online survey among medical students and physicians in Jordan. The survey covered demographics, familiarity to psychedelics and ketamine, attitudes toward their medical use, and concerns about risks and legality. Statistical analyses, including multivariate regression and factor analysis, assessed the influence of demographics on participant perspectives. Of the 1,985 respondents, most had limited familiarity to psychedelics. LSD was the most recognized substance, while fewer participants identified psilocybin or MDMA. familiarity and attitudes varied significantly by age, gender, and prior familiarity, with professional status showing no impact. Three attitude clusters emerged: opposers (<i>n</i> = 1000), cautious (<i>n</i> = 677), and supporters (<i>n</i> = 308), each influenced by different demographics. This study reveals a notable familiarity gap and mixed attitudes toward psychedelic therapies among Jordanian healthcare professionals, highlighting the need for targeted education to enhance understanding of these treatments in Jordan's medical community.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brian S Barnett, Miranda Arakelian, Jeremy Weleff, Tobias Squier-Roper, Franklin King, Drew Cumming, Tatiana Falcone
{"title":"Psychiatric Residents' Perspectives on Psychedelics and Psychedelic Assisted Therapy.","authors":"Brian S Barnett, Miranda Arakelian, Jeremy Weleff, Tobias Squier-Roper, Franklin King, Drew Cumming, Tatiana Falcone","doi":"10.1080/02791072.2025.2527296","DOIUrl":"https://doi.org/10.1080/02791072.2025.2527296","url":null,"abstract":"<p><p>This study evaluated the attitudes, knowledge, and educational experiences of psychiatry residents regarding psychedelics and psychedelic-assisted therapy (PAT). In 2023, we distributed an anonymous survey to United States psychiatry residents, assessing demographics, knowledge, and opinions on psychedelics/PAT. The survey also included items asking respondents to retrospectively self-report how strongly psychedelic-related work and educational opportunities influenced their career choice and ranking of residency programs in the Match. Of the 109 respondents, most reported limited formal education on psychedelics during training but expressed a strong desire for more instruction. Most believed psychedelics hold promise for psychiatric disorders (83.49%), though fewer saw similar potential for substance use disorders (55.96%). Notably, 39.81% reported psychedelic-related educational or research opportunities influenced residency program rankings, and 39.25% indicated the possibility of treating patients with psychedelics influenced their decision to pursue psychiatry. Higher knowledge scores and stronger belief in psychedelics' therapeutic potential were associated with greater self-reported influence of psychedelic-related opportunities on program ranking. This study is limited by its small sample size and potential for self-selection and recall bias. Overall, psychiatry residents demonstrated optimism about psychedelics' therapeutic potential but reported inadequate training. Expanding psychedelic-focused educational content in residency could better prepare trainees for psychedelics' evolving role in psychiatry.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ekaterina V Fedorova, Victoria Ryan, Janna Ataiants, Jim Seaberg, Maddy Finkelstein, Benjamin F Cocchiaro, Stephen E Lankenau
{"title":"Cannabis Practices and Cannabinoid/Terpene Preferences in Medical Cannabis Patients Who Use Cannabis for Pain and Anxiety.","authors":"Ekaterina V Fedorova, Victoria Ryan, Janna Ataiants, Jim Seaberg, Maddy Finkelstein, Benjamin F Cocchiaro, Stephen E Lankenau","doi":"10.1080/02791072.2025.2527292","DOIUrl":"https://doi.org/10.1080/02791072.2025.2527292","url":null,"abstract":"<p><p>Therapeutic potential of cannabinoids and terpenes in cannabis products is complicated by the possibility to alleviate pain yet exacerbate anxiety symptoms. Little is known about how cannabis practices, and preferences for cannabinoids and terpenes differ among medical cannabis patients who use cannabis to relieve pain, or anxiety, or both. A concurrent explanatory mixed-methods design was utilized. The quantitative analytical sample (<i>n</i> = 1,060) consisted of participants who self-reported past 90-day cannabis use to relieve: physical pain only (14.8%), feeling uptight/anxious only (29.5%), or both conditions (55.7%). We examined between-group differences in demographic variables, cannabis practices and preferences. Qualitative interviews with a subsample of patients (<i>n</i> = 39) were analyzed thematically regarding cannabinoid/terpene preferences to contextualize quantitative results. Compared to the <i>Anxiety-only</i> group, pain groups were more likely to use high potency flower/extract products (i.e., moon rocks/caviar), topicals/creams and CBD; the <i>Pain/anxiety</i> group was more likely to use Rick Simpson Oil and look for CBD, CBN, CBG and CBC. Both quantitative and qualitative data supported preferences for CBD and caryophyllene for pain relief, myrcene for pain and anxiety relief, while <i>Anxiety-only</i> group was less likely to prefer terpinolene. Future studies need to assess if cannabis practices and preferences are associated with symptom improvements over time.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Grace Stockwell, Nicholas R Hoeh, Francesca Fogarty, Cerys Clayden, Lisa Reynolds
{"title":"Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context.","authors":"Grace Stockwell, Nicholas R Hoeh, Francesca Fogarty, Cerys Clayden, Lisa Reynolds","doi":"10.1080/02791072.2025.2527299","DOIUrl":"https://doi.org/10.1080/02791072.2025.2527299","url":null,"abstract":"<p><p>Ketamine-assisted therapy (KAT) is a novel modality that shows promise as a treatment for depression. The current study sought to add to the scarce research in the area and inform future applications of KAT for patients with treatment-resistant depression. The study used in-depth qualitative interviews (<i>N</i> = 12) to explore participants' perceptions of KAT, including working with therapists, the ketamine experience, the therapeutic setting, and how these aspects impacted experiences and their lives following treatment. Thematic analysis indicated that preparation of mind-set supported therapeutic benefit, which was underscored by openness, clear therapeutic intentions, mindfulness, and understanding the mechanisms of how KAT works. Additionally, comfort in the setting supported participants to \"let go\" and was facilitated by learning about the therapist's personal experiences, a strong therapeutic alliance, and feeling safe. External physical cues such as music also influenced the experience, facilitating a spiritual journey guiding the experience. Words of caution were expressed where trauma had been unveiled and letting go had left participants feeling vulnerable. These findings provide a deeper understanding of the impact of contextual processes during KAT to inform future clinical trials and improve the clinical efficacy of KAT.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura C Carvalho, Jorge Encantado, Hannes Kettner, Christopher Timmerman, Diogo Veiga, Pedro J Teixeira
{"title":"A Scoping Review of Research in Naturalistic Studies with Psychedelics.","authors":"Laura C Carvalho, Jorge Encantado, Hannes Kettner, Christopher Timmerman, Diogo Veiga, Pedro J Teixeira","doi":"10.1080/02791072.2025.2520221","DOIUrl":"https://doi.org/10.1080/02791072.2025.2520221","url":null,"abstract":"<p><p>Psychedelic research has traditionally focused on controlled, clinical settings to evaluate the therapeutic potential of substances such as psilocybin. However, in recent years, there has been growing interest in naturalistic research, which explores psychedelic use in real-world settings. This review aims to critically analyze trends in naturalistic psychedelic research, focusing on sample demographics and the diversity of contextual factors across different settings. A systematic search in PubMed, PsycINFO, and Web of Science was conducted, including studies that involved the use of classic psychedelics in real-world settings. Two reviewers independently screened articles and extracted data on both sample and setting characteristics. A total of 103 studies were included, most of which employed a cross-sectional survey-based design (<i>n</i> = 54), with sample characteristics being widely reported, albeit with considerable variability across studies. Ayahuasca was the most frequently studied substance (66%), and ceremonial settings were the most commonly reported (35.9%). While sample characteristics were widely reported, there was significant variability. Specific contextual components, such as music, were often underreported, with longitudinal studies providing the most comprehensive details. This review highlights the need for systematic reporting standards in naturalistic psychedelic research to maximize its complementary value alongside clinical trials.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-14"},"PeriodicalIF":2.1,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martijn Koolen, Annika Wirsching, Erwin Krediet, Michiel van Elk
{"title":"Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study.","authors":"Martijn Koolen, Annika Wirsching, Erwin Krediet, Michiel van Elk","doi":"10.1080/02791072.2025.2508156","DOIUrl":"10.1080/02791072.2025.2508156","url":null,"abstract":"<p><p>Psychedelic-assisted psychotherapy (PAP) constitutes a novel treatment paradigm in mental health care practice that is currently being evaluated for its clinical efficacy and safety. Insight into the attitudes of clinicians toward PAP remains crucial for its successful integration into mental health care. This cross-sectional survey explores the attitudes of Dutch mental health care professionals toward PAP, specifically focusing on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder and psilocybin-assisted psychotherapy for major depressive disorder. The study included 198 clinicians who completed a 40-item online survey, distributed between April and May 2022. The study examined clinicians' attitudes toward PAP, the relation between these attitudes and several demographic variables, and clinicians' perceived implementation barriers. Respondents generally exhibited positive attitudes toward PAP, which in turn were related to previous use of either MDMA or psilocybin. Participants believed that psychiatrists and licensed psychologists were the ideal professionals to administer PAP, expressed concerns about their ability to establish a connection with patients during psychedelic states of consciousness, and preferred administering PAP in specialized facilities within hospital settings. This study provides valuable insights into the implementation of PAP and helps informing educational and training programs for clinicians, as well as integrating PAP into mental health care.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rafaelle Lancelotta, Meghan DellaCrosse, Diana Quinn, Syre Saniyah, Micah Saniyah, Natalie Gukasyan, Sasha Narayan, Aki Nikolaidis, Jae Sevelius, Alan K Davis
{"title":"Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study.","authors":"Rafaelle Lancelotta, Meghan DellaCrosse, Diana Quinn, Syre Saniyah, Micah Saniyah, Natalie Gukasyan, Sasha Narayan, Aki Nikolaidis, Jae Sevelius, Alan K Davis","doi":"10.1080/02791072.2025.2520224","DOIUrl":"https://doi.org/10.1080/02791072.2025.2520224","url":null,"abstract":"<p><p>This study investigated subjective psychedelic experiences in the global LGBTQIA+ population. Using validated measures of acute psychedelic effects, psychological flexibility, gender and sexual identity attitudes, adverse experiences, and mental health, we examined self-reported changes in identity and mental health outcomes following psychedelic use. A total of 346 individuals completed the survey. The sample was predominantly White (78.6%) with a mean age of 31.7 years. Over half were assigned female at birth (57.8%), and participants identified across diverse gender categories: women (28.9%), genderqueer (19.5%), nonbinary (17.6%), and men (15.9%). Participants reported lifetime use of classical psychedelics (<i>M</i> = 22.8) and MDMA (<i>M</i> = 11.3). Most (77.2%) endorsed the therapeutic potential of psychedelics for gender dysphoria, and 65.3% reported changes in gender identity attitudes post-experience. Retrospective self-reports indicated significant changes in sexual identity and commitment, with effects ranging from small to large. Mental health improvements included reductions in traumatic stress (d = 1.051), depression (d = 0.756), and anxiety (d = 0.859), and increased psychological flexibility (d = 0.996). Canonical correlation analysis identified a significant relationship (Rc = 0.49, <i>p</i> = .001) between the intensity of acute psychedelic effect and increases in self-acceptance and sexual identity exploration. These findings suggest that psychedelic experiences may positively impact mental health and facilitate identity exploration in LGBTQIA+ individuals. This study offers preliminary support for further research into the therapeutic potential of psychedelics within marginalized communities.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-14"},"PeriodicalIF":2.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pain Intensity and Hazardous Cannabis Use: The Moderating Role of Pain-related Anxiety.","authors":"Victoria E Carlin, Lisa R LaRowe, Joseph W Ditre","doi":"10.1080/02791072.2025.2511756","DOIUrl":"10.1080/02791072.2025.2511756","url":null,"abstract":"<p><p>Although cannabis has gained attention as a potential treatment for chronic pain, hazardous cannabis use (i.e. patterns of use that have harmful consequences) has been linked to negative health outcomes. Pain intensity is associated with greater cannabis use, and individuals with greater pain-related anxiety may be more likely to respond to pain with substance use. However, no prior work has examined the role of pain-related anxiety in hazardous cannabis use among individuals with chronic pain. The current analyses tested whether pain-related anxiety moderates associations between pain intensity and hazardous cannabis use. Participants included 80 cannabis users with chronic pain (63% male; 67% White; <i>M</i><sub><i>age</i></sub> = 33.6). Results indicated a positive interaction between pain intensity and pain-related anxiety on hazardous cannabis use (<i>p</i> < .05), such that pain intensity was positively associated with hazardous cannabis use among individuals with moderate and high pain-related anxiety, but not those with low pain-related anxiety, suggesting that pain-related anxiety may function as a transdiagnostic vulnerability factor for greater co-occurring pain and hazardous cannabis use. Future work should examine longitudinal associations between pain, pain-related anxiety, and hazardous cannabis use. There may be clinical utility in addressing pain-related anxiety among cannabis users with chronic pain.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study.","authors":"Brandon Biba, Brian A O'Shea","doi":"10.1080/02791072.2025.2511750","DOIUrl":"https://doi.org/10.1080/02791072.2025.2511750","url":null,"abstract":"<p><p>New methods that capture the public's perception of controversial topics may be valuable. This study investigates public sentiments toward psychedelics and other substances through analyzes of Reddit discussions, using Google's cloud-based Natural Language Processing (NLP) infrastructure. Our findings indicate that illicit substances such as heroin and methamphetamine are associated with highly negative general sentiments, whereas psychedelics like Psilocybin, LSD, and Ayahuasca generally evoke neutral to slightly positive sentiments. This study underscores the effectiveness and cost efficiency of NLP and machine learning models in understanding the public's perception of sensitive topics. The findings indicate that online public sentiment toward psychedelics may be growing in acceptance of their therapeutic potential. However, limitations include potential selection bias from the Reddit sample and challenges in accurately interpreting nuanced language using NLP. Future research should aim to diversify data sources and enhance NLP models to capture the full spectrum of public sentiment toward psychedelics. Our findings support the importance of ongoing research and public education to inform policy decisions and therapeutic applications of psychedelics.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Araam Abboud, Clay Schiebrel, Ramzi W Nahhas, Sam Durkin, Kyle Hua, Hannah Redding, Danielle Gainer
{"title":"Patients' Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment.","authors":"Araam Abboud, Clay Schiebrel, Ramzi W Nahhas, Sam Durkin, Kyle Hua, Hannah Redding, Danielle Gainer","doi":"10.1080/02791072.2025.2511752","DOIUrl":"https://doi.org/10.1080/02791072.2025.2511752","url":null,"abstract":"<p><p>This study examined patient perspectives on psilocybin therapy, specifically their acceptance and views on the therapeutic benefits of both hallucinogenic and non-hallucinogenic forms. A cross-sectional survey was conducted among psychiatric patients aged 18-65 at a community mental health center, assessing their attitudes, knowledge, and acceptance of psilocybin therapy. In total, 62.4% of the participants expressed openness to hallucinogenic psilocybin (<i>p</i> = .009), while 60.4% were open to non-hallucinogenic forms (<i>p</i> = .023). Patients with major depressive disorder preferred hallucinogenic therapy more (<i>p</i> = .010), while those with borderline personality disorder (BPD) (<i>p</i> = .030) and post-traumatic stress disorder (PTSD) (<i>p</i> = .035) favored non-hallucinogenic options, possibly due to concerns about the intensity of hallucinogenic experiences. Individuals with substance use disorder (SUD) demonstrated a greater acceptance of both hallucinogenic (<i>p</i> = .007) and non-hallucinogenic forms (<i>p</i> = .046) than individuals without SUD. These findings suggest that societal stigma is not a significant barrier to psilocybin therapy and that non-hallucinogenic forms may provide a more accessible option for certain patient groups. Understanding patient perspectives on psilocybin therapy, including vulnerability to adverse hallucinogenic experiences, can inform personalized and effective treatments for resistant conditions.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}